Compare GIS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIS | GH |
|---|---|---|
| Founded | 1866 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 22.9B |
| IPO Year | 2004 | 2018 |
| Metric | GIS | GH |
|---|---|---|
| Price | $32.24 | $167.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 26 |
| Target Price | $37.00 | ★ $200.24 |
| AVG Volume (30 Days) | ★ 9.6M | 1.8M |
| Earning Date | 09-23-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.49% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $2,037,800,000.00 | $982,021,000.00 |
| Revenue This Year | N/A | $38.23 |
| Revenue Next Year | $0.27 | $35.14 |
| P/E Ratio | $44.04 | ★ N/A |
| Revenue Growth | 4.11 | ★ 32.88 |
| 52 Week Low | $31.18 | $61.00 |
| 52 Week High | $49.71 | $191.05 |
| Indicator | GIS | GH |
|---|---|---|
| Relative Strength Index (RSI) | 33.62 | 46.52 |
| Support Level | $31.46 | $153.88 |
| Resistance Level | $34.49 | $173.94 |
| Average True Range (ATR) | 0.97 | 7.36 |
| MACD | -0.07 | -1.75 |
| Stochastic Oscillator | 22.20 | 22.06 |
General Mills is a global packaged-food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2025, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.